Corcept Therapeutics CORT announced that the FDA has issued a complete response letter (“CRL”) to its new drug application (“NDA”), seeking approval for its proprietary, selective cortisol modulator, ...

CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and hypercortisolism, a randomized placebo-controlled trial showed. Among 136 patients, ...

ORLANDO -- A surprisingly high prevalence of hypercortisolism was found in people with uncontrolled diabetes, according to the two-part, phase IV CATALYST study. Of 1,055 patients with ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Mifepristone reduced HbA1c and weight in patients with ...

ORLANDO, Florida — Almost a quarter of patients with poorly controlled type 2 diabetes enrolled in the prevalence-phase of a new study had hypercortisolism, suggesting there may need to be a shift in ...

Approximately one quarter (23.8%) of patients with difficult-to-control type 2 diabetes (T2D) had hypercortisolism, with contributing factors including older age; lower body mass index (BMI); ...

Presenter/Lead Investigator: Deepak L. Bhatt, MD, MPH, MBA, Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai and Director of Mount Sinai Fuster Heart ...

Please provide your email address to receive an email when new articles are posted on . In a cohort of patients with resistant hypertension, more than one-quarter had hypercortisolism. The results ...

CORT fell 50.4% after the FDA issued a complete response letter to the relacorilant NDA for hypercortisolism. FDA wants additional evidence of relacorilant's effectiveness, despite positive GRACE ...